Welcome to our dedicated page for Ernexa news (Ticker: ERNA), a resource for investors and traders seeking the latest updates and insights on Ernexa stock.
Ernexa Therapeutics develops cell therapies for advanced cancer and autoimmune disease using engineered induced pluripotent stem cells that are transformed into synthetic allogeneic induced mesenchymal stem cells. News about the company centers on ERNA-101, its lead iMSC candidate for ovarian cancer, including preclinical tumor-model results, immuno-oncology combinations and scientific discussions of the ovarian cancer treatment landscape.
Company updates also cover ERNA-201 for autoimmune inflammation, regulatory interactions tied to cell-therapy development, investor presentations, collaboration or market-entry programs, and capital-structure actions such as common-stock reverse splits and Nasdaq listing compliance.
Ernexa Therapeutics (Nasdaq: ERNA) reported continued operational progress and preclinical advancement on Nov 10, 2025. The company said its operating loss declined 44% year-over-year for the nine months ended Sept 30, 2025, and highlighted a partnership with Cellipont Bioservices to advance lead program ERNA-101 toward clinical trials.
Key program milestones disclosed include a 58.2% preclinical survival advantage for ERNA-101, planned completion of IND-enabling studies and an IND submission by Q1 2026, and a targeted first-in-human Phase 1 start in H2 2026. ERNA-201 remains in preclinical development with a pre-IND meeting anticipated by Q1 2026.
Ernexa Therapeutics (Nasdaq: ERNA) participated in a Virtual Investor “What This Means” segment on Nov. 6, 2025 to discuss a recently announced partnership with Cellipont Bioservices.
The agreement covers Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for ovarian cancer, into clinical manufacturing and clinical trials. President and CEO Sanjeev Luther represented the company in the segment. The presentation recording is available via the Virtual Investor platform.
Cellipont Bioservices and Ernexa Therapeutics (Nasdaq: ERNA) announced a collaboration on Oct 29, 2025 to advance ERNA-101, Ernexa's lead allogeneic iMSC cell therapy for ovarian cancer, into clinical manufacturing and trials. The agreement covers Engineering, Differentiation, and Production (EDP) activities and cGMP development and scale-up of the ERNA-101 manufacturing process.
ERNA-101 is an off-the-shelf iMSC therapy designed to reprogram immunologically "cold" tumors to "hot" ones; preclinical data were presented at AACR and ASCO. The partnership targets translating preclinical promise into a clinically viable therapy.
Cellipont Bioservices and Ernexa Therapeutics (ERNA) announced a manufacturing collaboration on Oct. 29, 2025 to advance ERNA-101, Ernexa's lead allogeneic iMSC cell therapy for ovarian cancer, toward clinical manufacturing and trials. The agreement covers engineering, differentiation, and production (EDP) activities and cGMP development and scale-up of the ERNA-101 process. ERNA-101 has shown preclinical potential to convert immunologically "cold" tumors into "hot" tumors, with data presented at AACR and ASCO. No financial terms or clinical timelines were disclosed.
Ernexa Therapeutics (Nasdaq: ERNA), a company focused on developing cell therapies for cancer and autoimmune diseases, will present at the Cell & Gene Meeting on the Mesa on October 7, 2025 in Phoenix, Arizona.
The company will showcase its pipeline, including ERNA-101, a cell therapy targeting ovarian cancer, and ERNA-201 for autoimmune disease treatment. Both therapies utilize Ernexa's proprietary synthetic, allogeneic induced mesenchymal stem cell (iMSC) technology to create off-the-shelf treatments.
Recently, Ernexa presented new data on ERNA-101 at the AACR Special Conference, demonstrating how their gene-modified iPSC-derived MSC technology improves the immune microenvironment in high-grade serous ovarian cancer.
Ernexa Therapeutics (Nasdaq: ERNA), a cell therapy company, announced that CEO Sanjeev Luther will participate in a panel discussion at the 5th Annual iPSC Drug Development Summit on October 1, 2025, in Boston.
The company is developing engineered induced mesenchymal stem cells (iMSC) therapies, including ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease. Ernexa's approach focuses on creating scalable, allogeneic, off-the-shelf treatments without requiring patient-specific cell harvesting. The company recently presented data on ERNA-101's ability to restore a "hot" immune microenvironment in high-grade serous ovarian cancer at an AACR Special Conference.
Ernexa Therapeutics (Nasdaq: ERNA) announced it will present new preclinical data for its lead cell therapy candidate ERNA-101 at the AACR Special Conference in Cancer Research on September 20, 2025. The presentation will focus on ERNA-101's ability to reprogram the ovarian tumor microenvironment.
The oral presentation, led by Dr. Michael Andreeff from MD Anderson Cancer Center, will showcase how ERNA-101, an off-the-shelf cell therapy using engineered induced pluripotent stem cells (iPSCs), can potentially activate the immune system to target cancer cells. The therapy demonstrates promise in restoring immune activity in difficult-to-treat ovarian tumors.
Ernexa Therapeutics (NASDAQ: ERNA), a cell therapy company focusing on cancer and autoimmune diseases, reported significant operational improvements for H1 2025. The company achieved a 51% reduction in operating loss to $5.2 million, down from $10.7 million in H1 2024. Total operating expenses decreased by 51% to $5.2 million, with general and administrative expenses dropping 66% to $2.8 million.
The company is advancing two key products: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease, both utilizing synthetic allogeneic induced mesenchymal stem cells (iMSCs) for off-the-shelf treatment. Lease expenses saw a dramatic 97% reduction to $0.1 million, primarily due to a sublease termination.
Ernexa Therapeutics (Nasdaq: ERNA), a biotechnology company focused on developing novel cell therapies, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.
The company's leadership will showcase their proprietary iMSC platform and two lead programs: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease treatment. The presentation will highlight their development of scalable, off-the-shelf cell therapies, with ERNA-101 expected to enter clinical trials by 2026.
Ernexa Therapeutics (Nasdaq: ERNA), a biotechnology company focused on cell therapies for cancer and autoimmune diseases, has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company received formal notice from Nasdaq on July 1, 2025, confirming its continued listing status.
CEO Sanjeev Luther reaffirmed the company's commitment to advancing their pipeline, with plans to initiate their first clinical trial in early 2026. The company's focus remains on developing engineered cell therapies for ovarian cancer and autoimmune disease patients.